PriCara, Ortho-McNeil now named Janssen Pharmaceuticals

August 5, 2011

PriCara and Ortho-McNeil, divisions of Ortho-McNeil-Janssen Pharmaceuticals, will operate under the name Janssen Pharmaceuticals, the family of companies announced this week. The change, effective immediately, is part of a global effort to unite the Janssen Pharmaceutical Companies around the world under a common identity and to increase collaboration, the statement said.

PriCara and Ortho-McNeil, divisions of Ortho-McNeil-Janssen Pharmaceuticals, will operate under the name Janssen Pharmaceuticals, the family of companies announced this week. The change, effective immediately, is part of a global effort to unite the Janssen Pharmaceutical Companies around the world under a common identity and to increase collaboration, the statement said.

The following therapies are now under the Janssen Pharmaceuticals’ new name:

Aciphex (rabeprazole sodium) for gastroesophageal reflux disease
Doribax (doripenem for injection) for intra-abdominal and urinary tract infections
Elmiron (pentosan polysulfate sodium) for interstitial cystitis
Nucynta (tapentadol) for the relief of moderate-to-severe acute pain
Xarelto (rivaroxaban tablets) for deep vein thrombosis

With this change, Janssen Pharmaceuticals is better positioned to provide greater innovation and to deliver on the promise of new treatments and new ways to improve the health of individuals with serious disease, the company said. Beyond the new name and logo, Janssen Pharmaceuticals said there will be no changes in legal structure.

 “This is an exciting time for our family of companies as we come together under 1 name,” said Jennifer Taubert, president, internal medicine, Janssen Pharmaceuticals.
“Uniting together under a common identity will allow us to operate more effectively and efficiently with the same passion and commitment that has led us to the forefront of patient care in our therapeutic areas.”

Related Content:

News | Clinical Pharmacology